PATENT

Our Docket: P41 90004

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wahl and O'Gorman

Serial No.: 08/486,409

Filed: June 7, 1995

FLP-MEDIATED GENE MODIFICA-

TION IN MAMMALIAN CELLS, AND COMPOSITIONS AND CELLS

USEFUL THEREFOR

BOX SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

Group Art Unit: Unassigned

Examiner: Unassigned

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trade-

marks, Washington, D.C. 20231 on .

By Deborah A. Dugan Reg. No. 37,915
08/16/95

Date of Signature

COMMUNICATION

Sir:

1

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES mailed August 4, 1995, the following are provided:

- a copy of the NOTICE; (1)
- (2) a copy of the sequence information in computer readable form;
- (3) a Preliminary Amendment with replacement pages 29-33;
- (4)a Statement Under 37 CFR §1.821 (f) and (q); and
- (5) a Appointment of Associate Attorney

Respectfully submitted,

Date: 08/16 /95

Deborah A. Dugan

Registration No. 37,315 Telephone: (619) 546-1995

Facsimile: (619) 546-9392

PRETTY, SCHROEDER, BRUEGGEMANN & CLARK 444 South Flower Street, Suite 2000 Los Angeles, California 90071

Application No. 48646

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acidesequence distributions of the control of the con
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is
directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the
computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRE Distance.
unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e)
as required by 37 CFR 1.821(e).
7. Other: ————————————————————————————————————
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
.1 \ X
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the
A statement that the content of the paper and computes a
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For questions regarding compliance with these requirements, please contact:
For Rules Interpretation, call (703) 308-1123
FOR CRF submission help, call (703) 308-4212
For Patentin software help, call (703) 308-6856

Please return a copy of this notice with your response.